These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 33911278)
1. It's time to invite more people to join clinical trials. Nature; 2021 Apr; 592(7856):659-660. PubMed ID: 33911278 [No Abstract] [Full Text] [Related]
2. FDA signals it's open to drug trials that shift midcourse. Mathews AW Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817 [No Abstract] [Full Text] [Related]
4. The coronavirus outbreak could make it quicker and easier to trial drugs. Ledford H Nature; 2020 Jun; 582(7811):172. PubMed ID: 32504019 [No Abstract] [Full Text] [Related]
6. Adaptive design of confirmatory trials: Advances and challenges. Lai TL; Lavori PW; Tsang KW Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372 [TBL] [Abstract][Full Text] [Related]
7. An overview of EMPaCT and fundamental issues affecting minority participation in cancer clinical trials: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual. Vickers SM; Fouad MN Cancer; 2014 Apr; 120 Suppl 7(0 7):1087-90. PubMed ID: 24643645 [No Abstract] [Full Text] [Related]
8. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506 [TBL] [Abstract][Full Text] [Related]
9. Design and statistical aspects of the management of clinical trials to assess antihypersensitivity product efficacy. Kaufman HW; Kleinberg I Arch Oral Biol; 1994; 39 Suppl():97S-100S. PubMed ID: 7702473 [TBL] [Abstract][Full Text] [Related]
10. Unabated increases in trial costs reflect evolving research milieu. Samson K Ann Neurol; 2009 Apr; 65(4):A9-11. PubMed ID: 19399857 [No Abstract] [Full Text] [Related]
11. Untying the Gordian knot. Su F; Zuppa AF; Adamson PC Anesth Analg; 2007 Apr; 104(4):993; author reply 993-4. PubMed ID: 17377125 [No Abstract] [Full Text] [Related]
12. The new FDA reality. Waksman R Cardiovasc Revasc Med; 2014 Jan; 15(1):1-2. PubMed ID: 24444470 [No Abstract] [Full Text] [Related]
13. Patients, physicians, and clinical trials: the other side of the coins. Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587 [No Abstract] [Full Text] [Related]
14. The needs of the few. Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796 [No Abstract] [Full Text] [Related]
15. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals. Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS Trials; 2016 Apr; 17():199. PubMed ID: 27079511 [TBL] [Abstract][Full Text] [Related]
16. FDA perspective on trials with interim efficacy evaluations. Temple R Stat Med; 2006 Oct; 25(19):3245-9; discussion 3326-47. PubMed ID: 16847824 [TBL] [Abstract][Full Text] [Related]
17. Translational research: 4 ways to fix the clinical trial. Ledford H Nature; 2011 Sep; 477(7366):526-8. PubMed ID: 21956311 [No Abstract] [Full Text] [Related]
18. A father's fight to help his sons - and fix clinical trials. Adam D Nature; 2019 Jan; 565(7738):148-151. PubMed ID: 30626961 [No Abstract] [Full Text] [Related]